Self-amplifying mRNA vaccines: Mode of action, design, development and optimization

Mohammad M. Pourseif; Yosef Masoudi-Sobhanzadeh; Erfan Azari; Sepideh Parvizpour; Jaleh Barar; Rais Ansari; Yadollah Omidi

doi:10.1016/j.drudis.2022.103341

Self-amplifying mRNA vaccines: Mode of action, design, development and optimization

Mohammad M. Pourseif
, Yosef Masoudi-Sobhanzadeh
, Erfan Azari
, Sepideh Parvizpour
, Jaleh Barar
, Rais Ansari
, Yadollah Omidi

Research output: Contribution to journal › Review article › peer-review

57 Scopus citations

Abstract

The mRNA-based vaccines are quality-by-design (QbD) immunotherapies that provide safe, tunable, scalable, streamlined and potent treatment possibilities against different types of diseases. The self-amplifying mRNA (saRNA) vaccines, as a highly advantageous class of mRNA vaccines, are inspired by the intracellular self-multiplication nature of some positive-sense RNA viruses. Such vaccine platforms provide a relatively increased expression level of vaccine antigen(s) together with self-adjuvanticity properties. Lined with the QbD saRNA vaccines, essential optimizations improve the stability, safety, and immunogenicity of the vaccine constructs. Here, we elaborate on the concepts and mode-of-action of mRNA and saRNA vaccines, articulate the potential limitations or technical bottlenecks, and explain possible solutions or optimization methods in the process of their design and development.

Original language	English
Article number	103341
Journal	Drug Discovery Today
Volume	27
Issue number	11
DOIs	https://doi.org/10.1016/j.drudis.2022.103341
State	Published - Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 Elsevier Ltd

Funding

The authors would like to acknowledge the Research Center for Pharmaceutical Nanotechnology (RCPN) at Tabriz University of Medical Sciences for the support (#68182).

Funders	Funder number
Tabriz University	68182

ASJC Scopus Subject Areas

Pharmacology
Drug Discovery

Keywords

Messenger RNA capping
polymerase
RNA-dependent RNA polymerase
self-amplifying mRNA
translation medicine
vaccine

Disciplines

Pharmacology
Pharmaceutics and Drug Design

Access to Document

10.1016/j.drudis.2022.103341

Cite this

@article{024a3b6c2ca1425db2d12ed022666f88,

title = "Self-amplifying mRNA vaccines: Mode of action, design, development and optimization",

abstract = "The mRNA-based vaccines are quality-by-design (QbD) immunotherapies that provide safe, tunable, scalable, streamlined and potent treatment possibilities against different types of diseases. The self-amplifying mRNA (saRNA) vaccines, as a highly advantageous class of mRNA vaccines, are inspired by the intracellular self-multiplication nature of some positive-sense RNA viruses. Such vaccine platforms provide a relatively increased expression level of vaccine antigen(s) together with self-adjuvanticity properties. Lined with the QbD saRNA vaccines, essential optimizations improve the stability, safety, and immunogenicity of the vaccine constructs. Here, we elaborate on the concepts and mode-of-action of mRNA and saRNA vaccines, articulate the potential limitations or technical bottlenecks, and explain possible solutions or optimization methods in the process of their design and development.",

keywords = "Messenger RNA capping, polymerase, RNA-dependent RNA polymerase, self-amplifying mRNA, translation medicine, vaccine",

author = "Pourseif, \{Mohammad M.\} and Yosef Masoudi-Sobhanzadeh and Erfan Azari and Sepideh Parvizpour and Jaleh Barar and Rais Ansari and Yadollah Omidi",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = nov,

doi = "10.1016/j.drudis.2022.103341",

language = "English",

volume = "27",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - Self-amplifying mRNA vaccines

T2 - Mode of action, design, development and optimization

AU - Pourseif, Mohammad M.

AU - Masoudi-Sobhanzadeh, Yosef

AU - Azari, Erfan

AU - Parvizpour, Sepideh

AU - Barar, Jaleh

AU - Ansari, Rais

AU - Omidi, Yadollah

PY - 2022/11

Y1 - 2022/11

N2 - The mRNA-based vaccines are quality-by-design (QbD) immunotherapies that provide safe, tunable, scalable, streamlined and potent treatment possibilities against different types of diseases. The self-amplifying mRNA (saRNA) vaccines, as a highly advantageous class of mRNA vaccines, are inspired by the intracellular self-multiplication nature of some positive-sense RNA viruses. Such vaccine platforms provide a relatively increased expression level of vaccine antigen(s) together with self-adjuvanticity properties. Lined with the QbD saRNA vaccines, essential optimizations improve the stability, safety, and immunogenicity of the vaccine constructs. Here, we elaborate on the concepts and mode-of-action of mRNA and saRNA vaccines, articulate the potential limitations or technical bottlenecks, and explain possible solutions or optimization methods in the process of their design and development.

AB - The mRNA-based vaccines are quality-by-design (QbD) immunotherapies that provide safe, tunable, scalable, streamlined and potent treatment possibilities against different types of diseases. The self-amplifying mRNA (saRNA) vaccines, as a highly advantageous class of mRNA vaccines, are inspired by the intracellular self-multiplication nature of some positive-sense RNA viruses. Such vaccine platforms provide a relatively increased expression level of vaccine antigen(s) together with self-adjuvanticity properties. Lined with the QbD saRNA vaccines, essential optimizations improve the stability, safety, and immunogenicity of the vaccine constructs. Here, we elaborate on the concepts and mode-of-action of mRNA and saRNA vaccines, articulate the potential limitations or technical bottlenecks, and explain possible solutions or optimization methods in the process of their design and development.

KW - Messenger RNA capping

KW - polymerase

KW - RNA-dependent RNA polymerase

KW - self-amplifying mRNA

KW - translation medicine

KW - vaccine

UR - https://www.scopus.com/pages/publications/85137355495

UR - https://www.scopus.com/pages/publications/85137355495#tab=citedBy

U2 - 10.1016/j.drudis.2022.103341

DO - 10.1016/j.drudis.2022.103341

M3 - Review article

C2 - 35988718

AN - SCOPUS:85137355495

SN - 1359-6446

VL - 27

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 11

M1 - 103341

ER -

Self-amplifying mRNA vaccines: Mode of action, design, development and optimization

Abstract

Bibliographical note

Funding

ASJC Scopus Subject Areas

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this